Evaluation of Serum Asprosin Levels in Patients with T2DM in Duhok District, Iraqi Kurdistan Region

Abstract

Asprosin was discovered to be an innovative hormone that is complemented in “adipose tissue” as well as is abnormally elevated in human and mice which are resistant to insulin. Nevertheless, data on the contribution of asprosin in the development of DM (T2DM) is still largely missing. Consequently, the main aim of this trial was to compare the serum asprosin concentration in people with T2DM to those of apparently healthy individuals who reside in Duhok district. This investigation was carried out between Sep. 2021 and Jan. 2022 at “Duhok diabetic center in Azadi teaching and Mazi non-government laboratory”. The levels of serum asprosin were measured in 180 participants (90 confirmed as with T2DM and 90 apparently healthy persons). All of the participants' height, weight, and biochemical variables were measured and compared. Biochemical markers including lipid panel, fasted blood sugar, hemoglobin A1c, and fasted insulin were analyzed via the “auto-analyzer system termed 6000 series COBASS”. While, the blood’s levels of asprosin were calculated through ELISA assay. The study's data was analyzed using “SPSS”. The mean age of adults with T2DM was (43.93 ± 11.95) and among those who appeared to be healthy was (41.09 ± 11.33). Serum asprosin levels were considerably higher in T2DM patients (17.21 ± 4.61) ng/ml than in healthy control (5.17 ± 2.96) (P value < 0.001). In addition, a strong relation existed among serum asprosin and BMI, TG, TCH, FBG, HbA1c, FI, and HOMA-IR (P value < 0.001), whereas an inverse relationship appeared between serum asprosin and HDL-C (P value < 0.01). This investigation proves that adults with T2DM had higher serum asprosin levels than those who seemed to be healthy. Additionally, in individuals with T2DM, serum asprosin was found to be strongly linked with BMI, FBG, FI, HOMAIR, TCH and TG (P value < 0.01).